---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-014186"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2024-11-04T23:59:59+00:00"
generated_at: "2026-05-30T05:56:33.581210+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech subsidiary Journey Medical receives FDA approval for Emrosi to treat rosacea in adults

## Summary
- FDA approved Emrosi (Minocycline HCL ER 40mg) for inflammatory lesions of rosacea; Journey Medical to market it in U.S.
- Phase 3 trials met all endpoints; Emrosi showed statistically significant superiority over Oracea® 40mg and placebo.
- Initial supply expected late Q1 or early Q2 2025; developed with Dr. Reddy’s Laboratories.
- Journey Medical is a majority-controlled subsidiary of Fortress Biotech (FBIO).

## SEC filing metadata
- accession: 0001558370-24-014186
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2024-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837024014186/0001558370-24-014186-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837024014186/fbio-20241104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-014186
- JSON: https://secwatch.observer/filing/0001558370-24-014186.json
- Plain text: https://secwatch.observer/filing/0001558370-24-014186.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.